Journal
BIOANALYSIS
Volume 6, Issue 18, Pages 2371-2383Publisher
FUTURE SCI LTD
DOI: 10.4155/bio.14.181
Keywords
-
Funding
- BMS
Ask authors/readers for more resources
Aim: To support drug development of a PEGylated anti-CD28 domain antibody, a sensitive and robust LC-MS/MS assay was developed for the first in-human multiple ascending dose study. Materials & methods: The procedure consists of a protein precipitation with acidified acetonitrile, followed by trypsin digestion of the supernatant. A surrogate peptide from the complementarity determining region was quantified with an LC-MS/MS assay using a stable isotope-labeled internal standard with flanking amino acids. An acid dissociation step was found to be essential to achieve full analyte recovery in the presence of antidrug antibodies and soluble target CD28. Results & conclusion: The fully validated LC-MS/MS assay demonstrates good accuracy (% deviation 6.3) and precision (%CV 5.2) with an lower limit of quantitation of 10 ng/ml.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available